Alpha Teknova, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Alpha Teknova reported Q2 2026 revenue of $12.2 million, up 18% from $10.3 million in Q2 2025, driven by growth across Lab Essentials ($9.2M, +18%) and Clinical Solutions ($2.4M, +18%). The company raised full-year 2026 revenue guidance to $45–47 million and improved Free Cash Outflow guidance to less than $8 million. Gross margin expanded to 40.1% from 38.7%, though the company remains unprofitable with Q2 net loss of $3.2 million (–$0.06/share) and six-month loss of $7.7 million (–$0.14/share).
Why this rating
Strong revenue growth and guidance raise relative to $53.5M market cap; margin expansion and cash-flow improvement are meaningful. Still unprofitable, but trajectory and new AI product (Build-Tek) support recovery narrative—meaningful for this size company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.